KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA Nov 10, 2023 07:01AM
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA Nov 1, 2023 07:01AM
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY Oct 23, 2023 07:01AM
Kazia announces voluntary delisting from ASX Oct 11, 2023 07:01AM
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS Oct 5, 2023 07:01AM


Sep 29, 2023 07:01AM KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Jul 6, 2023 07:00AM KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
Jun 8, 2023 07:00AM KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
May 25, 2023 07:01AM KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT
Apr 14, 2023 07:02AM Kazia (KZIA) Regains Compliance With Nasdaq Minimum Bid Price Requirement
Apr 14, 2023 07:01AM KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Apr 4, 2023 07:00AM KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
Dec 15, 2022 07:01AM KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
Dec 12, 2022 07:01AM KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
Dec 1, 2022 07:01AM COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
Nov 9, 2022 07:00AM KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Oct 27, 2022 07:00AM KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA
Oct 6, 2022 08:00AM PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY
Sep 9, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
Sep 8, 2022 08:30AM KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
Aug 5, 2022 08:40AM KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
Jul 12, 2022 08:15AM KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
Jul 6, 2022 07:00AM US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Jun 17, 2022 08:00AM US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Jun 13, 2022 07:00AM POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
Jun 7, 2022 07:00AM PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
Jun 3, 2022 07:00AM KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
May 31, 2022 07:00AM GBM AGILE OPENS TO PAXALISIB IN EUROPE
May 23, 2022 08:30AM KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
Apr 29, 2022 11:00AM KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
Apr 8, 2022 08:30AM KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
Apr 8, 2022 08:00AM TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
Mar 21, 2022 08:00AM KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
Feb 28, 2022 08:00AM PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
Feb 7, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
Jan 25, 2022 08:00AM KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
Jan 7, 2022 08:00AM KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
Dec 13, 2021 11:00AM KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER
Nov 29, 2021 08:00AM GBM AGILE Opens to Paxalisib in Canada
Nov 15, 2021 11:00AM Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
Nov 11, 2021 08:00AM PNOC Study in Childhood Brain Cancer Enrols First Patient
Oct 6, 2021 10:00AM Kazia Therapeutics to Present at LD Micro Main Event
Sep 10, 2021 12:30PM Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
Jul 21, 2021 10:00AM Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
Jun 30, 2021 10:00AM Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
Jun 15, 2021 10:01AM Kazia (KZIA) Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
Jun 15, 2021 10:00AM Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
Jun 7, 2021 08:00AM Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
Jun 3, 2021 07:00AM Kazia Therapeutics to Present at LD Micro Invitational XI
Apr 19, 2021 05:36AM Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE